Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview

Rhea-AI Summary

Compugen Ltd. (NASDAQ: CGEN) announced its participation in the JMP Securities C-Suite Series, scheduled for January 30, 2023, at 11:00 am ET. CEO Anat Cohen-Dayag and other management team members will discuss the company's advancements in the DNAM-1 axis. A live webcast of the event will be available on Compugen's Investor Relations webpage, with a replay accessible afterward. Compugen specializes in cancer immunotherapies and has developed several promising product candidates, including COM701 and COM902 for solid tumors, with ongoing collaborations such as the AZD2936 program with AstraZeneca.

HOLON, Israel, Jan. 23, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohen-Dayag, Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities C-Suite Series to discuss Compugen's leadership in the DNAM-1 axis. The fireside chat will take place on Monday, January 30, 2023, at 11:00 am ET.

A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com.  A replay will also be available following the live event.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Partnered programs include a PD-1/TIGIT bispecific derived from COM902 (AZD2936) in Phase 2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The most advanced program, COM503 is about to enter pre-IND enabling studies. COM503 is a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com  
Tel: +1 (628) 241-0071  

View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-the-jmp-securities-c-suite-series--tigit-landscape-overview-301727997.html

SOURCE Compugen Ltd.

FAQ

When is Compugen's virtual fireside chat at the JMP Securities C-Suite Series?

Compugen's virtual fireside chat will take place on January 30, 2023, at 11:00 am ET.

Who will represent Compugen in the upcoming fireside chat?

CEO Anat Cohen-Dayag and additional members of the management team will participate in the fireside chat.

How can I watch the live webcast of Compugen's fireside chat?

The live webcast can be accessed on Compugen's Investor Relations section at www.cgen.com.

What is the focus of the discussion during Compugen's fireside chat?

The discussion will focus on Compugen's leadership in the DNAM-1 axis.

What are some of Compugen's product candidates mentioned in the press release?

Some of Compugen's product candidates include COM701, a potential first-in-class anti-PVRIG antibody, and COM902, targeting TIGIT for solid tumors.